CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 9 of the 17 sources its claims cite were checked for support.
Abstract
BACKGROUND: . METHODS: After conducting preclinical in vitro and in vivo studies, we evaluated the safety and pharmacodynamic effects of single escalating doses of NTLA-2001 in six patients with hereditary ATTR amyloidosis with polyneuropathy, three in each of the two initial dose groups (0.1 mg per kilogram and 0.3 mg per kilogram), within an ongoing phase 1 clinical study. RESULTS: after a single dose. Serial assessments of safety during the first 28 days after infusion in patients revealed few adverse events, and those that did occur were mild in grade. Dose-dependent pharmacodynamic effects were observed. At day 28, the mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the group that received a dose of 0.1 mg per kilogram and was 87% (range, 80 to 96) in the group that received a dose of 0.3 mg per kilogram. CONCLUSIONS: . (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051.).
Overview
CoChat Summary
TL;DR
In six patients with hereditary ATTR amyloidosis with polyneuropathy, single intravenous doses of NTLA-2001, a CRISPR-Cas9 lipid nanoparticle therapy, produced dose-dependent reductions in serum TTR protein at day 28 and only mild adverse events. This interim phase 1 study provides early clinical proof of concept for in vivo CRISPR-Cas9 gene editing.
Key findings
- At day 28, mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the 0.1 mg/kg group and 87% (range, 80 to 96) in the 0.3 mg/kg group.
- Adverse events occurred in three of six patients and were all grade 1 (mild); no serious adverse events were observed. One patient had a grade 1 infusion-related reaction, and increased d-dimer levels in five of six patients returned to baseline by day 7.
- Preclinical studies showed durable TTR knockout after a single dose: in primary human hepatocytes, NTLA-2001 had EC50 0.05 to 0.15 nmol/L and EC90 0.17 to 0.67 nmol/L, with ≥93.7% TTR editing and ≥95% reduction in TTR protein production; in cynomolgus monkeys, a single dose of Cyn-LNP at 3 or 6 mg/kg produced maximum whole-liver gene editing of 73% and >94% reduction in serum TTR protein sustained over 12 months.
Methods
- Interim results from two initial dose groups of a two-part, global, phase 1, open-label, multicenter study: six patients with hereditary ATTR amyloidosis with polyneuropathy received a single intravenous dose of NTLA-2001 at 0.1 mg/kg or 0.3 mg/kg (three patients each) between November 2020 and April 2021.
- Key eligibility included age 18 to 80 years, polyneuropathy due to hATTR amyloidosis with or without cardiomyopathy, body weight 50 to 90 kg, and lack of access to approved ATTR treatments; prior TTR stabilizers were permitted after washout.
- Serum TTR protein was measured by validated enzyme-linked immunosorbent assay at baseline and weeks 1, 2, and 4; analyses were descriptive, comparing baseline with day 28 as mean percentage change and range. Preclinical work included primary human hepatocytes, transgenic mice, and cynomolgus monkeys.
Limitations
- The paper states that the study involves a very small number of patients with limited follow-up to date, and that continued serial measurements are planned to confirm durability. It also states that these are interim results from the first two dose groups in an ongoing dose-escalation study.
- Evident from the text: the clinical portion is open-label with no control group, uses descriptive analyses only, reports safety and pharmacodynamic effects through day 28, and does not report clinical outcomes such as disease progression, quality of life, or mortality.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 1 Not valid · 5 Not checked · 56 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“TTR, which has a normal physiological role in vitamin A transport. 31”
What the sources say
- Supportedcites [31] 31. Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Eur J Heart Fail 2020; 22: 39-53. source
The Introduction states that TTR physiologically transports retinol-binding protein. The Therapeutic antisense oligonucleotides section links this function to vitamin A levels, supporting the paraphrase that TTR normally plays a role in vitamin A transport. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“but are limited by the requirement for long-term administration to maintain TTR knockdown.”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Trial Design and Regimens section reports patisiran infusions every three weeks for 18 months, and Pharmacodynamics reports sustained TTR reduction during that period. The paper does not establish that long-term administration is required to maintain knockdown after treatment stops, or that this limitation applies to current ATTR treatments generally. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [13] 13. Adams D, Polydefkis M, GonzálezDuarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an openlabel extension study. Lancet Neurol 2021; 20: 49-59. source
- Partly supportedcites [14] 14. Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019; 139: 431-43. sourceExperimental — accuracy not yet measured
The Methods (Study Design and Treatment; page unavailable) report patisiran infusions every three weeks for 18 months, and the introductory passage describes its reduction of TTR protein. The paper does not establish that long-term administration is required to maintain TTR knockdown or characterize that requirement as a limitation of current ATTR treatments generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More extensive TTR knockdown is associated with greater improvement in neuropathic end points in patients with hATTR polyneuropathy. 12”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Primary End Point section reports a correlation between the degree of TTR reduction and change in mNIS+7, a composite neuropathy measure, at 18 months. The paper reports improvements in other end points, but our copy does not link the extent of knockdown to improvement across those end points. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“circulating TTR is produced almost entirely (>99%) within the liver, 2”
What the sources say
- Partly supportedcites [2] 2. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015; 66: 2451-66. sourceExperimental — accuracy not yet measured
The section labeled “Diagnosis and Classification” says TTR is synthesized primarily in the liver, supporting the liver as its main source. It does not give the claimed >99% figure for circulating TTR. No page number is available in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Inotersen is associated with serious side effects, including glomerulonephritis and decreased platelet counts. 17”
What the sources say
- Supportedcites [17] 17. Gertz MA, Scheinberg M, Waddington-Cruz M, et al. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-medi- - ated amyloidosis. Expert Rev Clin Pharmacol 2019; 12: 701-11. source
The Safety and tolerability section (p. 9) reports decreased platelet counts and glomerulonephritis in patients receiving inotersen, including severe cases. The Regulatory affairs section (p. 9) states that the US approval carries a black box warning for increased risks of thrombocytopenia and glomerulonephritis. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
43 more claims · 1 with their cited sources checked
Create a free account to see all 69 claims and every source verdict.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“which has already lead to investigational new drugs in clinical trials (NCT04601051)”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Gillmore et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Ionizable lipid nanoparticles (LNPs) are a promising non-viral delivery platform for mRNA nanomedicines (13, 14) that have been used to deliver siRNA and CRISPR-based gene editing therapies to the liver in postnatal mouse, non-human primate, and clinical studies with encouraging results (15–18).”
From Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease (2023) · cites this paper as [17]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationCRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Cited by
Items 201–300 of 1,725
Non-Coding RNAs as Novel Regulators of Neuroinflammation in Alzheimer’s Disease
Liu, Y., Cheng, X. M., Li, H., Hui, S., Zhang, Z., Yang, X. J., & Peng, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.908076 · Cited by 71
Sniper2L is a high-fidelity Cas9 variant with high activity
Kim, Y.-H., Kim, N., Okafor, I. C., Choi, S.-C., Min, S., Lee, J., Bae, S.-M., Choi, K., Choi, J., Harihar, V., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01279-5 · Cited by 74
Clinical applications of gene therapy for rare diseases: A review
Papaioannou, I., Owen, J. S., & Yáñez‐Muñoz, R. J. (2023) · International Journal of Experimental Pathology · doi:10.1111/iep.12478 · Cited by 79
An Update on the Application of CRISPR Technology in Clinical Practice
Morshedzadeh, F., Ghanei, M., Lotfi, M., Ghasemi, M., Ahmadi, M., Najari-Hanjani, P., Sharif, S., Mozaffari‐Jovin, S., Peymani, M., & Abbaszadegan, M. R. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00724-z · Cited by 71
“This level of response, besides a few adverse events observed in this trial, could be scaled satisfactorily for the treatment to be offered to all ATTR patients [134].”
mRNA therapies: Pioneering a new era in rare genetic disease treatment
Shen, G., Liu, J., Yang, H., Xie, N., & Yang, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.056 · Cited by 63
Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine
González-López, E., Maurer, M. S., & García‐Pavía, P. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae811 · Cited by 67
Aboobakar, I. F., & Wiggs, J. L. (2022) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.14035 · Cited by 64
Tschöpe, C., & Elsanhoury, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082148 · Cited by 68
“Preliminary results from six hereditary ATTR-polyneuropathy patients enrolled in phase 1, open-label, multicenter study warrant further evaluation (NCT04601051) [87].”
BackgroundUniversal Barcoding Predicts In Vivo ApoE-Independent Lipid Nanoparticle Delivery
Sanchez, A. J. D. S., Dobrowolski, C. N., Cristian, A., Echeverri, E. S., Zhao, K., Hatit, M. Z. C., Loughrey, D., Paunovska, K., & Dahlman, J. E. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c01133 · Cited by 66
CRISPR nuclease off-target activity and mitigation strategies
Wienert, B., & Cromer, M. K. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.1050507 · Cited by 77
“For instance, when a therapeutic editing approach targets a coding sequence—like knocking out a pathogenic gene to correct a disease phenotype (Gillmore et al., 2021)—an array of indels will form at the cut site.”
BackgroundMethodInfluentialThe CRISPR/Cas9 System Delivered by Extracellular Vesicles
Zhu, X., Gao, M., Yang, Y., Li, W., Bao, J., & Li, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030984 · Cited by 65
Breaking the mold with RNA—a “RNAissance” of life science
Jones, C. H., Androsavich, J. R., So, N., Jenkins, M. P., MacCormack, D., Prigodich, A. E., Welch, V., True, J. M., & Dolsten, M. (2024) · npj Genomic Medicine · doi:10.1038/s41525-023-00387-4 · Cited by 73
“Currently, advancements in LNP delivery systems and chemical modi fi cations of single-stranded RNA are being combined to ensure ef fi cient delivery of mRNA with gRNAs for CRISPR-Cas9 gene editing 34,35 .”
CRISPR–Cas9 delivery strategies for the modulation of immune and non-immune cells
Alsaiari, S. K., Eshaghi, B., Du, B., Kanelli, M., Li, G., Wu, X., Zhang, L., Chaddah, M., Lau, A., Yang, X., et al. (2024) · Nature Reviews Materials · doi:10.1038/s41578-024-00725-7 · Cited by 70
“ester-modified PEG LNPs co-loaded with Cas9 mRNA and sgRNA achieving 16.4% editing confined to the retinal pigment epithelium 137,138 .”
InfluentialTransthyretin: Its function and amyloid formation
Ueda, M. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105313 · Cited by 69
Targeting nucleic acid-based therapeutics to tumors: Challenges and strategies for polyplexes
Vetter, V. C., & Wagner, E. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.013 · Cited by 65
Applications of Gene Therapy in Cardiomyopathies
Argiro, A., Bui, Q., Hong, K. N., Ammirati, E., Olivotto, I., & Adler, E. (2024) · JACC: Heart Failure · doi:10.1016/j.jchf.2023.09.015 · Cited by 59
Dynamic carriers for therapeutic RNA delivery
Berger, S., Lächelt, U., & Wagner, E. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307799120 · Cited by 66
“In contrast to standard liposomes or polyplexes, the LNP architecture is highly adaptable for efficient packaging of different nucleic acid cargos, ranging from small siRNA (22) to large CRISPR/Cas9 mRNA (23).”
Backgroundde Boer, R. A., Heymans, S. R. B., Backs, J., Carrier, L., Coats, A. J. S., Dimmeler, S., Eschenhagen, T., Filippatos, G. S., Gepstein, L., Hulot, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2414 · Cited by 62
Stern, L. K., & Patel, J. K. (2022) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1050 · Cited by 64
Nanobiomaterial vectors for improving gene editing and gene therapy
Hu, S. W., Ding, T., Tang, H., Guo, H., Cui, W., & Shu, Y. (2023) · Materials Today · doi:10.1016/j.mattod.2023.04.011 · Cited by 61
Current trends of clinical trials involving CRISPR/Cas systems
Zhang, S., Wang, Y., Mao, D., Wang, Y., Zhang, H., Pan, Y., Wang, Y., Teng, S., & Huang, P. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1292452 · Cited by 70
“Among the clinical trials we screened, one (NCT04601051) was a clinical evaluation of the in vivo gene editing therapeutic agent NTLA-2001, which used LNPs to encapsulate Cas9 mRNA and a sgRNA targeting the TTR gene (136).”
BackgroundCRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination
Herskovitz, J., Hasan, M., Patel, M., Blomberg, W. R., Cohen, J. D., Machhi, J., Stein, D., Schroder, E. A., McMillan, J., Gurumurthy, C. B., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103678 · Cited by 66
“Furthermore, early-stage success of Intellia’s Clinical Trial (NCT04601051) for in vivo CRISPR Cas9 editing for patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and shows the promise of using in vivo gene therapy [45].”
BackgroundThe power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy
Guo, N., Liu, J., Li, W., Ma, Y., & Fu, D. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.11.018 · Cited by 70
The Role of Recombinant AAV in Precise Genome Editing
Bijlani, S., Pang, K. M., Sivanandam, V., Singh, A., & Chatterjee, S. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.799722 · Cited by 68
In vivo CRISPR gene editing in patients with herpetic stromal keratitis
Wei, A., Yin, D., Zhai, Z., Ling, S., Le, H., Tian, L., Xu, J., Paludan, S. R., Cai, Y., & Hong, J. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.08.021 · Cited by 67
Molecular Mechanisms of Cardiac Amyloidosis
Saito, Y., Nakamura, K., & Ito, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010025 · Cited by 50
“3 mg/kg CRISPR/Cas9 targeting TTR and achieved an 87% reduction of serum TTR levels at day 28 [9].”
BackgroundSystematic decomposition of sequence determinants governing CRISPR/Cas9 specificity
Fu, R., He, W., Dou, J., Villarreal, O. D., Bedford, E., Wang, H., Hou, C., Zhang, L., Wang, Y., Ma, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28028-x · Cited by 54
“(3) CNN_std is a deep learning model to predict off-target effects using a standard convolutional neuron network27 and the source codes to implement CNN_std were downloaded from https://github.”
Rapid and definitive treatment of phenylketonuria in variant-humanized mice with corrective editing
Brooks, D. L., Carrasco, M. J., Qü, P., Peranteau, W. H., Ahrens‐Nicklas, R. C., Musunuru, K., Alameh, M., & Wang, X. (2023) · Nature Communications · doi:10.1038/s41467-023-39246-2 · Cited by 57
“We further note that LNP-mediated CRISPR editing has achieved success in the clinic 23 and that an LNP drug product with ABE8.”
Biscaia-Caleiras, M., Fonseca, N. A., Lourenço, A. S., Moreira, J. N., & Simões, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.021 · Cited by 62
Artificial Intelligence and Cardiovascular Genetics
Krittanawong, C., Johnson, K. W., Choi, E., Kaplin, S. L., Venner, E., Murugan, M., Wang, Z., Glicksberg, B. S., Amos, C. I., Schatz, M. C., et al. (2022) · Life · doi:10.3390/life12020279 · Cited by 63
“Hence, genetic screening of TTR may, thus, prove to be increasingly useful in the future as it may allow susceptible patients to be identified and treated appropriately at an earlier stage of disease [10].”
BackgroundTargeting strategies for mRNA delivery
Meyer, R. A., Neshat, S. Y., Green, J. J., Santos, J. L., & Tuesca, A. D. (2022) · Materials Today Advances · doi:10.1016/j.mtadv.2022.100240 · Cited by 61
Foley, R. A., Sims, R. A., Duggan, E. C., Olmedo, J. K., Ma, R., & Jonas, S. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.973326 · Cited by 65
“, 2021), transthyretin amyloidosis (NCT04601051) (Gillmore et al., 2021) and Leber congenital amaurosis 10 (NCT03872479) (Mullard, 2019) demonstrate the potential to treat monogenetic disorders with a single, consistent base pair mutation.”
BackgroundSex differences in transthyretin cardiac amyloidosis
Aimo, A., Panichella, G., Garofalo, M., Gasparini, S., Arzilli, C., Castiglione, V., Vergaro, G., Emdin, M., & Maffei, S. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10339-w · Cited by 47
“Both patisiran and inotersen are approved for the treatment of patients with ATTR-familial amyloidotic PN. [66].”
BackgroundHematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease
Germino-Watnick, P., Hinds, M., Le, A., Chu, R., Liu, X., & Uchida, N. (2022) · Cells · doi:10.3390/cells11111843 · Cited by 68
Thin filament cardiomyopathies: A review of genetics, disease mechanisms, and emerging therapeutics
Keyt, L. K., Duran, J. M., Bui, Q. M., Chen, C., Miyamoto, M. I., Enciso, J. S., Tardiff, J. C., & ADLER, E. D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.972301 · Cited by 50
In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications
Huang, K. L., Zapata, D. A., Tang, Y., Teng, Y., & Li, Y. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121876 · Cited by 66
Nano-bio interactions in mRNA nanomedicine: Challenges and opportunities for targeted mRNA delivery
Saiding, Q., Zhang, Z., Chen, S., Xiao, F., Chen, Y., Li, Y., Zhen, X., Khan, M. M., Chen, W., Koo, S., et al. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115116 · Cited by 61
Masarwy, R., Stotsky‐Oterin, L., Elisha, A., Hazan‐Halevy, I., & Peer, D. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115359 · Cited by 61
Nanoparticle-Based Delivery Strategies for Combating Drug Resistance in Cancer Therapeutics
Park, S., Lu, G., Zheng, Y., Davison, E. K., & Li, Y. (2025) · Cancers · doi:10.3390/cancers17162628 · Cited by 69
“In addition, in early-phase trials of CRISPR/Cas9 LNPs for liver disorders, researchers already face dose-limiting cytokine release, strict off-target surveillance and tailored consent processes for irreversible genome edits [251,252].”
Makkar, S. K. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1675209 · Cited by 80
Robust, Durable Gene Activation In Vivo via mRNA-Encoded Activators
Beyersdorf, J. P., Bawage, S. S., Iglesias, N., Peck, H. E., Hobbs, R. A., Wroe, J. A., Zurla, C., Gersbach, C. A., & Santangelo, P. J. (2022) · ACS Nano · doi:10.1021/acsnano.1c10631 · Cited by 52
Substituting racemic ionizable lipids with stereopure ionizable lipids can increase mRNA delivery
Sanchez, A. J. D. S., Zhao, K., Huayamares, S. G., Hatit, M. Z. C., Lokugamage, M. P., Loughrey, D., Dobrowolski, C. N., Wang, S., Kim, H., Paunovska, K., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.037 · Cited by 55
Interactions of Apolipoproteins with Lipid-Based Nanoparticles
Dalhaimer, P., Florey, B., & Isaac, S. (2023) · ACS Nano · doi:10.1021/acsnano.2c10790 · Cited by 54
Feng, S., Xie, X., Liu, J., Li, A., Wang, Q., Guo, D., Li, S., Li, Y., Wang, Z., Guo, T., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02139-z · Cited by 65
“Developing new LNPs composition, such as NTLA2001 LNPs [152] and 306-O12B-LNPs [153], can achieve targeting delivery of the CRISPR/Cas system with excellent editing efficiency and safety.”
BackgroundDing, L., Cao, S., Qu, C., Wu, Y., & Yu, S. (2024) · ACS Sensors · doi:10.1021/acssensors.3c02571 · Cited by 55
Self-assembling protein nanoparticles for cytosolic delivery of nucleic acids and proteins
Eweje, F., Ibrahim, V., Shajii, A., Walsh, M. L., Ahmad, K., Alrefai, A., Miyasato, D. L., Davis, J. R., Ham, H. O., Li, K., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02664-2 · Cited by 66
Lipid Nanoparticles for Delivery of CRISPR Gene Editing Components
Wu, F., Li, N., Xiao, Y., Palanki, R., Yamagata, H. M., Mitchell, M. J., & Han, X. (2025) · Small Methods · doi:10.1002/smtd.202401632 · Cited by 73
Konstantinidis, E., Molisak, A., Perrin, F., Streubel-Gallasch, L., Fayad, S., Kim, D. Y., Petri, K., Aryee, M. J., Aguilar, X., György, B., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.03.022 · Cited by 66
“More recently, a clinical trial using CRISPR-Cas9 against hereditary transthyretin amyloidosis also entered the phase I stage in the first clinical trial for gene therapies of amyloid-related diseases.(38) With regard to AD, no studies in humans have been initiated, but systemic delivery of CRISPR components in transg…”
Hypercompact adenine base editors based on a Cas12f variant guided by engineered RNA
Kim, D. Y., Chung, Y., Lee, Y., Jeong, D., Park, K., Chin, H. J., Lee, J. M., Park, S., Ko, S., Ko, J., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01077-5 · Cited by 54
Intelligent nanotherapeutic strategies for the delivery of CRISPR system
Chen, C., Zhong, W., Du, S., Li, Y., Zeng, Y., Liu, K., Yang, J., Guan, X., & Han, X. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.013 · Cited by 59
Improving the sensitivity of in vivo CRISPR off-target detection with DISCOVER-Seq+
Zou, R. S., Liu, Y., Gaido, O. E. R., Konig, M. F., Mog, B. J., Shen, L. L., Avilés-Vázquez, F. J., Marín-González, A., & Ha, T. (2023) · Nature Methods · doi:10.1038/s41592-023-01840-z · Cited by 58
“DISCOVER-Seq+ has the potential to validate the specificity profile of genome editing at numerous stages of the therapeutic development pipeline, from cell lines and primary cells to mice and potentially non-human primates [1,18,31,32,35-37].”
BackgroundInfluentialAlves, C. R. R., Ha, L. L., Yaworski, R., Sutton, E. R., Lazzarotto, C. R., Christie, K. A., Reilly, A., Beauvais, A., Doll, R. M., de la Cruz, D., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01132-z · Cited by 76
“Early indications from clinical trials utilizing genome editing technologies to treat other diseases indicate that one-time persistent treatments may be within reach 80,81 .”
Chemical engineering of CRISPR–Cas systems for therapeutic application
Barber, H. M., Pater, A. A., Gagnon, K. T., Damha, M. J., & O’Reilly, D. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01086-0 · Cited by 65
“Preclinical studies in transgenic mice showed that NTLA-2001 knocks down TTR expression after a single administration 195 .”
InfluentialHigh‐Precision Synthesis of RNA‐Loaded Lipid Nanoparticles for Biomedical Applications
Seo, H., Jeon, L., Kwon, J., & Lee, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202203033 · Cited by 54
Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing
Whitley, J. A., & Cai, H. (2023) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12343 · Cited by 61
“Cas9 mRNA and sgRNA are encapsulated into LNPs and delivered via intravenous (IV) administration for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (NCT04601051) (Gillmore et al., 2021).”
BackgroundBrooks, D. L., Whittaker, M. N., Qü, P., Musunuru, K., Ahrens‐Nicklas, R. C., & Wang, X. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2023.10.005 · Cited by 54
Li, X., Li, J., Wei, J., Du, W., Su, C., Shen, X., Zhao, A., & Xu, M. (2025) · MedComm · doi:10.1002/mco2.70414 · Cited by 72
Epigenetic basis and targeting of cancer metastasis
Banerjee, R., Smith, J., Eccles, M. R., Weeks, R. J., & Chatterjee, A. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.11.008 · Cited by 54
Chiti, F., & Kelly, J. W. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2021.11.009 · Cited by 51
Progress of delivery methods for CRISPR-Cas9
Yang, W., Yan, J., Zhuang, P., Ding, T., Chen, Y., Zhang, Y., Zhang, H., & Cui, W. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2100342 · Cited by 57
“conducted a clinical trial that included six patients with ATTR [131].”
BackgroundMethodInfluentialBloom, M., & Gorevic, P. (2023) · Annals of Internal Medicine · doi:10.7326/aitc202303210 · Cited by 23
Deng, Y., Long, Y., Song, A., Wang, H., Xiang, S., Qiu, Y., Ge, X., Golberg, D. V., & Weng, Q. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c01705 · Cited by 49
Lipid nanoparticle-mediated mRNA delivery to CD34+ cells in rhesus monkeys
Kim, H., Zenhausern, R., Gentry, K., Lian, L., Huayamares, S. G., Radmand, A., Loughrey, D., Podilapu, A. R., Hatit, M. Z. C., Ni, H., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02470-2 · Cited by 72
Gene therapy for cystic fibrosis: Challenges and prospects
Sui, H., Xu, X., Su, Y., Gong, Z., Yao, M., Liu, X., Zhang, T., Jiang, Z., Bai, T., Wang, J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1015926 · Cited by 60
“, 2019) and in transthyretin amyloidosis by disrupting the disease-causing allele (Gillmore et al., 2021).”
BackgroundCellular Trafficking of Nanotechnology‐Mediated mRNA Delivery
Huang, P., Deng, H., Wang, C., Zhou, Y., & Chen, X. S. (2023) · Advanced Materials · doi:10.1002/adma.202307822 · Cited by 56
Nanoplatform‐Based In Vivo Gene Delivery Systems for Cancer Therapy
Luo, R., Le, H., Wu, Q., & Gong, C. (2024) · Small · doi:10.1002/smll.202312153 · Cited by 53
Kim, Y., Landstrom, A. P., Shah, S. H., Wu, J. C., & Seidman, C. E. (2024) · Circulation · doi:10.1161/cir.0000000000001296 · Cited by 91
“…the mutant gene allele through the CRISPR/Cas9 nuclease sys-tem while preserving the other allele with normal DNA sequences are being investigated in both animal models 28 and human patients 29 with CVD. Gene therapies for CVD caused by haploinsufficiency are also under active investigation.”
Toward Gene Transfer Nanoparticles as Therapeutics
Kavanagh, E. W., & Green, J. J. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102145 · Cited by 48
Modern therapeutic approaches to liver-related disorders
Gardin, A., Remih, K., Gonzales, E. M., Andersson, E. R., & Strnad, P. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.015 · Cited by 51
Guerriaud, M., & Kohli, É. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1012497 · Cited by 53
Gene Therapy Strategies Targeting Aging-Related Diseases
Yu, J., Li, T., & Zhu, J. (2022) · Aging and Disease · doi:10.14336/ad.2022.00725 · Cited by 70
“Although the publication of NTLA-2001 for Transthyretin Amyloidosis marked the first step toward in vivo CRISPR gene editing product [34], it was granted orphan drug by the United States Food and Drug Administration (FDA) and its success has limited expansibility.”
BackgroundInsights into the Mechanism of CRISPR/Cas9-Based Genome Editing from Molecular Dynamics Simulations
Bhattacharya, S., & Satpati, P. (2022) · ACS Omega · doi:10.1021/acsomega.2c05583 · Cited by 57
Small extracellular vesicle-mediated CRISPR-Cas9 RNP delivery for cardiac-specific genome editing
Mun, D., Kang, J., Kim, H., Yun, N., & Joung, B. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.05.023 · Cited by 49
Advances in the design and delivery of RNA vaccines for infectious diseases
Lokras, A. G., Bobak, T. R., Baghel, S. S., Sebastiani, F., & Foged, C. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115419 · Cited by 56
Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery
Haque, M. A., Shrestha, A., Mikelis, C. M., & Mattheolabakis, G. (2024) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2024.100283 · Cited by 97
“In different approaches, Intellia Therapeutics has developed the very first CRISPR/CAS9 single guide (sg)RNA encapsulated LNP, NTLA-2001 (NCT04601051) against transthyretin (hATTR)-amyloidosis (Gillmore et al., 2021; Lee et al., 2023b).”
BackgroundMessenger RNA-Based Therapeutics and Vaccines: What’s beyond COVID-19?
Li, D., Liu, C., Li, Y., Tenchov, R., Sasso, J. M., Zhang, D., Li, D., Zou, L., Wang, X., & Zhou, Q. A. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00047 · Cited by 53
Jang, H. J., Shah, N. M., Maeng, J. H., Liang, Y., Basri, N. L., Ge, J., Qu, X., Mahlokozera, T., Tzeng, S., Williams, R. B., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01880-x · Cited by 62
“Another exciting alternative is to use CRISPR technology 70–72 to increase the expression of targeted, endogenous loci that generate immunogenic antigens.”
CRISPR-Cas9 Gene Therapy: Non-Viral Delivery and Stimuli-Responsive Nanoformulations
Lee, H., Rho, W., Kim, Y.-H., Chang, H., & Jun, B. (2025) · Molecules · doi:10.3390/molecules30030542 · Cited by 64
“A larger Phase 1 trial is progress [81].”
Moving toward genome-editing therapies for cardiovascular diseases
Musunuru, K. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148555 · Cited by 50
“Interim results with single doses of LNPs encapsulating both Cas9 mRNA and a synthetic guide RNA targeting TTR, administered to six patients, demonstrated successful knockdown of blood transthyretin levels by as much as 96% at 1 month after treatment (57).”
BackgroundEngineered Cas12i2 is a versatile high-efficiency platform for therapeutic genome editing
McGaw, C., Garrity, A. J., Munoz, G., Haswell, J. R., Sengupta, S., Keston-Smith, E., Hunnewell, P., Ornstein, A., Bose, M., Wessells, Q. N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30465-7 · Cited by 46
Packer, M. S., Chowdhary, V., Lung, G., Cheng, L.-I., Aratyn-Schaus, Y., Leboeuf, D., Smith, S., Shah, A. A., Chen, D. L., Zieger, M. V., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.040 · Cited by 49
Directing the Way—Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery
Steffens, R. C., & Wagner, E. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03385-w · Cited by 53
“3 mg/kg); mild adverse effects [19] 52 Pharmaceutical Research (2023) 40:47–76”
BackgroundMethodIn vivo correction of cystic fibrosis mediated by PNA nanoparticles
Piotrowski-Daspit, A. S., Barone, C., Lin, C.-Y., Deng, Y., Wu, D. H., Binns, T. C., Xu, E., Ricciardi, A. S., Putman, R., Garrison, A., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo0522 · Cited by 54
On the mechanism of tissue-selective gene delivery by lipid nanoparticles
Kimura, S., & Harashima, H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.052 · Cited by 49
Yi, J., Lei, X., Guo, F., Chen, Q., Chen, X., Zhao, K., Zhu, C., Cheng, X., Lin, J., Yin, H., et al. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105618 · Cited by 46
Polyplex designs for improving the stability and safety of RNA therapeutics
Uchida, S., Lau, C. Y. J., Oba, M., & Miyata, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114972 · Cited by 52
CRISPR delivery with extracellular vesicles: Promises and challenges
Berggreen, A. H., Petersen, J. L., Lin, L., Benabdellah, K., & Luo, Y. (2023) · Journal of Extracellular Biology · doi:10.1002/jex2.111 · Cited by 53
“In contrast to EVs, LNPs have been investigated in a preclinical study that exhibited promising results for delivering CRISPR RNA to liver cells in patients suffering from transthyretin amyloidosis (Gillmore et al., 2021; Henderson, 2023).”
Volodina, O., & Smirnikhina, S. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01070-4 · Cited by 59
“High efficiency of gene editing may have been achieved due to delivery method, researchers developed LNP formulation specifically for liver targeting, lipoplexes were endocytosed by hepatocytes through low-density lipoprotein receptor [53].”
Gene therapy and genome editing for lipoprotein disorders
Gurevitz, C., Bajaj, A., Khera, A. V., Do, R., Schunkert, H., Musunuru, K., & Rosenson, R. S. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf411 · Cited by 51
TAPE-seq is a cell-based method for predicting genome-wide off-target effects of prime editor
Kwon, J., Kim, M., Bae, S.-M., Jo, A., Kim, Y.-H., & Lee, J. K. (2022) · Nature Communications · doi:10.1038/s41467-022-35743-y · Cited by 49
The progress of molecules and strategies for the treatment of HBV infection
Pan, Y., Xia, H., He, Y., Zeng, S., Shen, Z., & Huang, W. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1128807 · Cited by 48
“As for the delivery efficiency by lipid nanoparticles in vivo, the non-viral delivery of Cas9 mRNA and ribonucleoproteins has considerable potential for use in liver-targeted delivery in clinics (Gillmore et al., 2021).”
Background2024 Update on Classification, Etiology, and Typing of Renal Amyloidosis: A Review
Leung, N., & Nasr, S. H. (2024) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.01.530 · Cited by 43
Recent Therapeutic Gene Editing Applications to Genetic Disorders
Deneault, É. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46050255 · Cited by 64
“This opened the way for clinical trials of NTLA-2001 (NCT04601051 and NCT05697861) by Intellia Therapeutics, Cambridge, MA, USA, which showed no evidence of off-target editing in primary human hepatocytes using computational modeling, biochemical cell-free assays, and in vitro cellular assays [127].”
MethodCardiovascular Burden of the V142I Transthyretin Variant
Selvaraj, S., Claggett, B. L., Shah, S. H., Mentz, R. J., Khouri, M. G., Manichaikul, A. W., Khan, S. S., Rich, S. S., Mosley, T. H., Levitan, E. B., et al. (2024) · JAMA · doi:10.1001/jama.2024.4467 · Cited by 46
Self-citationJCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 67
Cardiac Amyloidosis: A Review of Current Imaging Techniques
Razvi, Y., Patel, R., Fontana, M., & Gillmore, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.751293 · Cited by 44
“Interim findings from a first-in-human dose escalation study of the CRISPR-Cas9 therapeutic, NTLA-2001, were extremely encouraging with patients achieving up to 96% knockdown of circulating TTR concentration following a single infusion (53).”
BackgroundSelf-citationEngineering of efficiency-enhanced Cas9 and base editors with improved gene therapy efficacies
Yin, S., Zhang, M., Liu, Y., Sun, X., Guan, Y., Chen, X., Yang, L., Huo, Y., Yang, J., Zhang, X., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.014 · Cited by 50
Khor, Y. M., Cuddy, S. A. M., Singh, V., Falk, R. H., Carli, M. F. D., & Dorbala, S. (2022) · Radiology · doi:10.1148/radiol.221082 · Cited by 59
Liposome-Based Carriers for CRISPR Genome Editing
Yin, X., Harmancey, R., McPherson, D. D., Kim, H., & Huang, S. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612844 · Cited by 45
Exosome-mediated delivery of CRISPR-Cas9: A revolutionary approach to cancer gene editing
Balaraman, A. K., Babu, M. A., Moglad, E. H. O., Mandaliya, V. B., Rekha, M. M., Gupta, S., Prasad, G. V. S., Kumari, M., Chauhan, A. S., Ali, H., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155785 · Cited by 52
Metadata
- Authors
- Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J. E., McKee, M. D., Schiermeier, A., Harari, O., Murphy, A., Kyratsous, C. A., Zambrowicz, B., Soltys, R., Gutstein, D. E., Leonard, J., Sepp-Lorenzino, L., & Lebwohl, D.
- Affiliations
- University of Auckland (NZ)
- From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George’s University of London (J.T.) — both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) — all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 493-502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177445623
- Cited by
- 1,801
- References
- 35
- Citations by year
- 2026: 349 · 2025: 332 · 2024: 368 · 2023: 336 · 2022: 328 · 2021: 84
- FWCI
- 228.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Intellia Therapeutics
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- transthyretin amyloidosis, hereditary ATTR amyloidosis, CRISPR/Cas9 genome editing, in vivo gene therapy, prealbumin, polyneuropathy, single ascending dose, pharmacodynamics, safety
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Female, Humans, Infusions, Intravenous, Liposomes, Male, Middle Aged, Prealbumin, RNA, Messenger, RNA, Guide, Kinetoplastida, Gene Transfer Techniques, Amyloid Neuropathies, Familial, Nanoparticles, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.



